

References

I-9129

1. Preferred Drug List (PDL) Prior Authorization Criteria. North Dakota Department of Health and Human Services. Medical Services Division. <http://www.hidesigns.com/ndmedicaid>
2. Entyvio prescribing information. Takeda Pharmaceuticals America, Inc. August 2021.
3. Feuerstein, Joseph D., et al. American Gastroenterological Association Clinical Practice Guideline on the Medical Management of Moderate to Severe Luminal and Perianal Fistulizing Crohn's Disease. *Gastroenterology* 2021; 160: 2496-2508.
4. MacDermott, Richard P, MD., et al. Treatment of Crohn disease in adults: Dosing and monitoring of tumor necrosis factor-alpha inhibitors. UpToDate. Last Updated June 2018. Literature review current through March 2019.
5. Lichtenstein G. R., Loftus E. V., Isaacs K. L., Regueiro M. D., Gerson L. B., Sands B. E. ACG clinical guideline: management of Crohn's disease in adults. *The American Journal of Gastroenterology*. 2018;113(4):481–517. doi: 10.1038/ajg.2018.27.
6. Rubin, D. T., MD, FACP, Ananthakrishnan, A. N., MD, MPH, Siegel, C. A., MD, MS, Sauer, B. G., MD, MSc, FACP, & Long, M. D., MD, MPH, FACP. ACG Clinical Guideline: Ulcerative Colitis in Adults. *The American Journal of Gastroenterology*. 2019; 114:384-413. Retrieved March 8, 2019, from <http://s3.gi.org/physicians/guidelines/UlcerativeColitis.pdf>